Menu

Image of the Day: Delayed Gratification

Eighty years ago, a Neanderthal femur dating back more than 120,000 years was recovered from a Southwestern Germany cave. Now, the ancient bone reveals new clues about the bedfellows of human ancestors. 

Jul 7, 2017
The Scientist Staff

Hohlenstein-Stadel Cave in Southwestern Germany, where an ancient, 124,000-year-old hominin femur was excavated in 1937

© PHOTO MUSEUM ULM

   In a study published this week (July 4) in Nature Communications, mitochondrial DNA from a Neanderthal femur, unearthed in 1937 from a Southwestern Germany cave, sheds light on the migration and mating patterns of human ancestors.

See “Neanderthal-Human Interbreeding Got an Early Start

124,000-year-old Neanderthal femur

OLEG KUCHAR © PHOTO MUSEUM ULM

    See C. Posth et al., “Deeply divergent archaic mitochondrial genome provides lower time boundary for African gene flow into Neanderthals,” Nature Communications, doi:10.1038/ncomms16046, 2017.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.